Coya Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $243.7K | $251.1K | $4.0M | $3.6M | $163.6K | $257.9K | $2.0K | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $2.3M | $3.8M | $3.3M | $2.6M | $2.9M | $2.7M | $2.1M | $2.2M |
| Operating Income | $-7.0M | $-7.6M | $-6.0M | $-2.4M | $-6.4M | $-7.7M | $-4.1M | $-4.5M |
| Operating Margin | -2,891.1% | -3,042.1% | -152.3% | -68.3% | -3,920.5% | -2,976.9% | -209,031.5% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-6.6M | $-7.2M | — | — | $-6.1M | $-7.3M | — | — |
| Income Tax Expense | — | — | — | — | $0 | — | — | — |
| Net Income | $-6.6M | $-7.2M | $-5.7M | $-2.1M | $-6.1M | $-7.3M | $-2.9M | $-4.0M |
| Net Margin | -2,723.4% | -2,869.6% | -144.2% | -59.4% | -3,725.2% | -2,833.4% | -149,373.8% | — |
| EPS (Basic) | $-0.28 | $-0.32 | $-0.34 | $-0.13 | $-0.36 | $-0.44 | $-0.18 | $-0.26 |
| EPS (Diluted) | $-0.28 | $-0.32 | $-0.34 | $-0.13 | $-0.36 | $-0.44 | $-0.18 | $-0.26 |
| Shares Outstanding (Basic) | 23.5M | 22.6M | 16.7M | 16.7M | 16.7M | 16.7M | 15.2M | 15.2M |
| Shares Outstanding (Diluted) | 23.5M | 22.6M | 16.7M | 16.7M | 16.7M | 16.7M | 15.2M | 15.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |